Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have been increasingly used in cancer therapy. Understanding the treatment-related adverse events of these drugs is critical for clinical practice.

Related collections

Author and article information

Journal

Title: JAMA Oncology

Abbreviated Title: JAMA Oncol

Publisher: American Medical Association (AMA)

ISSN (Print): 2374-2437

Publication date (Electronic): April 25 2019

Affiliations

[1 ]Division of Hematology, Mayo Clinic, Rochester, Minnesota

[2 ]Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota

[3 ]Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston

[4 ]Department of Public Health Sciences, Pennsylvania State College of Medicine, Hershey

[5 ]Medical School of Nanjing University, Nanjing, China

[6 ]The Comprehensive Cancer Centre of Drum Tower Hospital, Clinical Cancer Institute of Nanjing University, Nanjing, China

[7 ]Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston

[8 ]Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

[9 ]West Cancer Center, The University of Tennessee, Memphis

[10 ]Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston

Article

DOI: 10.1001/jamaoncol.2019.0393

PMC ID: 6487913

PubMed ID: 31021376

SO-VID: 3892eafd-ffac-4838-8a3c-406fea305e50

History

Data availability:

Comments

Comment on this article

scite_

Cited by 316

See all cited by

- Version 1
- Version 1

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials : A Systematic Review and Meta-analysis

Read this article at